Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07264660?
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
What's Your Reaction?
